Biohaven Debt to Equity Ratio 2016-2023 | BHVN
Current and historical debt to equity ratio values for Biohaven (BHVN) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Biohaven debt/equity for the three months ending March 31, 2023 was 0.00.
| Biohaven Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2023-03-31 |
$0.15B |
$0.47B |
0.31 |
| 2022-12-31 |
$0.12B |
$0.54B |
0.23 |
| 2022-09-30 |
$0.04B |
$0.10B |
0.35 |
| 2022-06-30 |
$2.19B |
$-0.81B |
-2.72 |
| 2022-03-31 |
$1.84B |
$-0.47B |
-3.94 |
| 2021-12-31 |
$0.11B |
$0.04B |
3.10 |
| 2021-09-30 |
$1.72B |
$-0.59B |
-2.91 |
| 2021-06-30 |
$1.30B |
$-0.46B |
-2.85 |
| 2021-03-31 |
$1.28B |
$-0.28B |
-4.61 |
| 2020-12-31 |
$1.08B |
$-0.39B |
-2.75 |
| 2020-09-30 |
$1.00B |
$-0.21B |
-4.66 |
| 2020-06-30 |
$0.46B |
$-0.04B |
-12.96 |
| 2020-03-31 |
$0.41B |
$0.12B |
3.37 |
| 2019-12-31 |
$0.35B |
|
0.00 |
| 2019-09-30 |
$0.32B |
$0.12B |
2.69 |
| 2019-06-30 |
$0.30B |
$0.19B |
1.63 |
| 2019-03-31 |
$0.15B |
$0.10B |
1.53 |
| 2018-12-31 |
$0.14B |
$0.15B |
0.92 |
| 2018-09-30 |
$0.13B |
$0.07B |
1.96 |
| 2018-06-30 |
$0.12B |
$0.12B |
1.01 |
| 2018-03-31 |
$0.02B |
$0.11B |
0.17 |
| 2017-12-31 |
$0.02B |
$0.13B |
0.11 |
| 2017-09-30 |
$0.03B |
$0.16B |
0.18 |
| 2017-06-30 |
$0.02B |
$0.19B |
0.11 |
| 2017-03-31 |
$0.04B |
$0.02B |
1.96 |
| 2016-12-31 |
$0.03B |
$-0.00B |
-16.32 |
| 2016-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2016-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2016-03-31 |
$0.00B |
|
0.00 |
| 2015-12-31 |
$0.00B |
$0.00B |
0.74 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.059B |
$0.463B |
|
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
|
